1-5 of 5
Yoshitaka Sekido
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TEAD-Independent Cell Growth of Hippo-Inactive Mesothelioma Cells: Unveiling Resistance to TEAD Inhibitor K-975 through MYC Signaling Activation

Ken Akao, Tatsuhiro Sato, Emi Mishiro-Sato, Satomi Mukai, Farhana Ishrat Ghani, Lisa Kondo-Ida, Kazuyoshi Imaizumi, Yoshitaka Sekido
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF11.
https://doi.org/10.1158/1535-7163.MCT-24-0308
Published: 03 January 2025
View article titled, TEAD-Independent Cell Growth of Hippo-Inactive Mesothelioma Cells: Unveiling Resistance to TEAD Inhibitor K-975 through MYC Signaling Activation
Open the PDF for TEAD-Independent Cell Growth of Hippo-Inactive Mesothelioma Cells: Unveiling Resistance to TEAD Inhibitor K-975 through MYC Signaling Activation in another window
Includes: Supplementary data
Journal Articles

Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells

Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Masaki Ishida, Hayato Kawachi, Yohei Matsui, Ryota Nakamura, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Yoshitaka Sekido, Shinsaku Tokuda, Koichi Takayama
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 212–222.
https://doi.org/10.1158/1535-7163.MCT-23-0138
Published: 01 February 2024
View article titled, Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
Open the PDF for Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells in another window
Includes: Supplementary data
Journal Articles

Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Shigeki Nanjo, Daisuke Ishikawa, Takako Sano, Kenji Kita, Takahiro Nakamura, Kunio Matsumoto, Kenichi Suda, Tetsuya Mitsudomi, Yoshitaka Sekido, Toshimitsu Uenaka, Seiji Yano
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2149–2157.
https://doi.org/10.1158/1535-7163.MCT-12-0195
Published: 09 October 2012
View article titled, Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <em>EGFR</em>-Mutant Lung Cancer
Open the PDF for Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <em>EGFR</em>-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B7: TSU‐68 suppresses the progression of malignant pleural mesothelioma cells in SCID mice by inhibiting angiogenesis

Trung The Van, Takuya Kuramoto, Hisatsugu Goto, Soji Kakiuchi, Tetsuo Taniguchi, Yoshitaka Sekido, Yasuhiko Nishioka, Saburo Sone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B7.
https://doi.org/10.1158/1535-7163.TARG-09-B7
Published: 10 December 2009
View article titled, Abstract B7: TSU‐68 suppresses the progression of malignant pleural mesothelioma cells in SCID mice by inhibiting angiogenesis
Journal Articles

The mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity of cisplatin, carboplatin and gemcitabine in human lung cancer cell lines

Yoshitsugu Horio, Jun-ichi Shimizu, Hirotaka Osada, Toyoaki Hida, Yoshinori Hasegawa, Kaoru Shimokata, Takashi Takahashi, Yoshitaka Sekido, Yasushi Yatabe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C136.
Published: 01 November 2007
View article titled, The mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity of cisplatin, carboplatin and gemcitabine in human lung cancer cell lines